Curative-Intent Metastasis-Directed Therapies for Molecularly Defined Oligorecurrent Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Curative-Intent Metastasis-Directed Therapies for Molecularly-Defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Eur Urol 2021 Mar 05;[EPub Ahead of Print], RM Glicksman, U Metser, D Vines, J Valliant, Z Liu, PW Chung, RG Bristow, A Finelli, R Hamilton, NE Fleshner, N Perlis, AR Zlotta, D Green, A Bayley, J Helou, S Raman, G Kulkarni, C Catton, T Lam, R Chan, P Warde, M Gospodarowicz, DA Jaffray, A BerlinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.